Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Extension CombiRx data show no benefit of combined MS drugs
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Repurposing drugs for disease modification in multiple sclerosis
Chemotherapeutics in the treatment of multiple sclerosis.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Intas launches biosimilar version of Rituximab
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Genzyme provides update on U.S. LEMTRADA™ filing
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.

Pages